Marques L. Bradshaw

MedicineEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.”.

A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.363

N/A

0DataRank · unranked

1 citations

Liping Du, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah +9 more

Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4109

N/A

0DataRank · unranked

0 citations

Aman Chauhan, Liping Du, Katharine Thomas, Aasems Jacob, Aimee Schad +13 more